NCRA vs LIXT vs ONCY vs RELI vs IMVT

For growth investors, Reliance Global Group, Inc.

(RELI) is the stronger pick with 2. 3% revenue growth year-over-year, versus -35. 2% for Nocera, Inc. (NCRA). Analysts rate Oncolytics Biotech Inc. (ONCY) a "Buy" — based on 10 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Immunovant, Inc.

(IMVT) delivered a total return of +205. 0%, compared to -100. 0% for Reliance Global Group, Inc. (RELI). Over 10 years, the gap is even starker: IMVT returned +212. 7% versus RELI's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Lixte Biotechnology Holdings, Inc.

(LIXT) is the lower-risk stock at 1. 19β versus Nocera, Inc. 's 1. 68β — meaning NCRA is approximately 41% more volatile than LIXT relative to the S&P 500. On balance sheet safety, Immunovant, Inc. (IMVT) carries a lower debt/equity ratio of 0% versus 4% for Reliance Global Group, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Reliance Global Group, Inc.

(RELI) is pulling ahead at 2. 3% versus -35. 2% for Nocera, Inc. (NCRA). On earnings-per-share growth, the picture is similar: Lixte Biotechnology Holdings, Inc. grew EPS 20. 8% year-over-year, compared to -11. 1% for Nocera, Inc.. Over a 3-year CAGR, RELI leads at 13. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Lixte Biotechnology Holdings, Inc.

(LIXT) is the more profitable company, earning 0. 0% net margin versus -64. 5% for Reliance Global Group, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: LIXT leads at 0. 0% versus -54. 8% for RELI. At the gross margin level — before operating expenses — RELI leads at 18. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Lixte Biotechnology Holdings, Inc.

(LIXT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 19)). Nocera, Inc. (NCRA) carries a higher beta of 1. 68 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (LIXT: -22. 2%, NCRA: -97. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (NCRA (Consumer Defensive) and LIXT (Healthcare) and ONCY (Healthcare) and RELI (Financial Services) and IMVT (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.